Compass says depression drug has long-lasting benefits
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
Evidence dossier
Intelligence passport
Measured timeline
📍 How it ended
Compass Pathways announced six-month data from a second Phase 3 trial confirming a rapid and durable profile for its depression treatment. The company touted these long-lasting benefits ahead of a year-end filing.
A launch is being eyed for the first half of 2027.
Epilogue added 101d ago, after coverage quieted.
Coverage (5)
-
-
-
Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 LaunchPsychedelic Alpha · 103d ago
-
-
Compass says depression drug has long-lasting benefitsSTAT · 103d ago
The brief
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Compass Pathways has released six-month data from its second Phase 3 trial (COMP006). The company states that the data confirms a rapid and durable profile for its depression drug, leading to an increase in company shares.
Coverage from STAT, Endpoints News, and Business Wire emphasizes the durability of the drug's benefits. Psychedelic Alpha and Moomoo highlight the positive late-stage trial results and the subsequent market reaction.
According to coverage, the company is planning a year-end filing and targeting a launch in the first half of 2027.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 101d ago.
Quick answers
What trial data was recently released?
Compass Pathways announced six-month data from its second Phase 3 trial, known as COMP006.
What is the nature of the drug being tested?
The drug is a psilocybin-based treatment for depression.
When is the treatment expected to launch?
Coverage indicates a target launch in H1 2027.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
Can GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depression
10 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Cerevance rescues its Parkinson's drug with phase 3 win
7 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Common Antidepressants Could Have an Unexpected Role in Cancer Survival
Unexpected link found between antidepressants and cancer survival rates.
How a Promising Pancreatic Cancer Drug Loses Its Punch
A Phase 3 trial launches a new drug duo for RAS G12D pancreatic cancer amid low five‑year survival rates.
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
10 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Vera kidney drug Trutakna shows strong final results in Phase 3 trial
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.